Project Grant R03HL180898
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $242K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to discover novel biomarkers and biological mechanisms underlying early-stage heart failure (HF). The $147,486 award to Duke University will support the development of an automated computational phenotype to identify early-stage HF, which will then be applied to large population cohorts. The research aims to leverage multi-omics data integration and...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $190,491 to Beth Israel Deaconess Medical Center, Inc. to conduct research on plasma protein markers of the blood pressure response during exercise and their relation to incident hypertension and cardiovascular disease. The project aims to identify circulating proteins associated with exercise blood pressure that could serve as predictive markers for future...
- This Project Grant award of $784,362.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., will support research investigating the role of body composition, coronary microvascular dysfunction, and heart failure with preserved ejection fraction in characterizing adverse cardiometabolic disease phenotypes. The research aims to leverage novel imaging technologies to identify mechanisms of...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $614,431.51 to the Rutgers University School of Nursing to quantify lactate metabolism in the heart. The key objectives are to use isotope tracers to measure lactate production and consumption fluxes in normal cardiomyocytes and hearts (K99 Aim 1), define metabolic changes in the pyruvate-lactate axis in chronic heart failure patients undergoing left ventricular...
- The University of Alabama at Birmingham (UAB) received a $637,732 project grant from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on improving the cardiac microenvironment as a novel strategy against diabetic ischemic heart failure. The project aims to leverage insights from cellular secretome research to transform treatment strategies for diabetic ischemic heart failure. Specifically, the research will investigate how...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center (VUMC) provides $173,352 to conduct research on the molecular characterization of frailty and functional limitations in heart failure with preserved ejection fraction (HFpEF). The key objectives are to measure associations between the human proteome and measures of multi-organ function in HFpEF, and to identify and prioritize...
- This Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences Program (CFDA 47.049) provides $640,562 to Duke University to develop advanced computer models that act as "virtual replicas" of a patient's blood vessels and heart activity. Using data from wearable sensors, the investigators will simulate how blood flows and interacts with vessel walls over time, enabling large-scale in silico testing of medical devices and therapies without...
- This federal Project Grant award of $650,028, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project at the University of California, Los Angeles (UCLA) to investigate the role of phosphodiesterases in regulating cyclic AMP signaling, excitation-contraction coupling, and arrhythmias in heart failure. The key objectives are to determine the differential effects of phosphodiesterase 4D signaling on cardiac...
- This federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the use of NNMT inhibition to treat heart failure. The $736,089 grant supports research to determine if increased NNMT activity, leading to NAD+ deficiency, is central to the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $422,894 to support research examining the interactive effects of cardiorespiratory fitness and adiposity on the recovery of impaired glucose and vascular control following a period of physical inactivity. The award period is from April 20, 2025 to March 31, 2028. The key objectives of the project are to: 1) investigate how existing health status...